The choice reflects the company's aims to revolutionize chronic care and expand global health solutions through innovative ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

A Harvard Business School Healthcare Alumni Association Q&A with Stephanie J. Creary, Assistant Professor of Management at ...

The AI-driven collaboration will use Syntekabio’s DeepMatcher platform to identify new therapeutic targets for MetaVia’s DA-1241 following promising Phase IIa trial (NCT06054815) results in patients ...

One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation ...